NCT00131443已完成2 期
A Double-Blind Dose Comparison Study of Topiramate in Pediatric Subjects With Basilar/Hemiplegic Migraine
Monarch Medical Research2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2004年2月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
- 试验地点
- 2
- 主要终点
- The primary efficacy outcome will be the reduction in average monthly migraine-days over the entire double-blind phase relative to the prospective baseline period
研究概览
简要总结
The objective of this study is to assess the effectiveness and safety of topiramate in the prevention of basilar and hemiplegic migraine in children and adolescents.
详细描述
The objective of this study is to assess the efficacy and safety of topiramate in the prophylaxis of basilar migraine and hemiplegic migraine in children and adolescents, by comparing two doses, 25 and 100 mg/day.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 盲法
- Double
入排标准
- 年龄范围
- 6 Years 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must meet International Headache Society (IHS) classification of pediatric migraine with aura: familial hemiplegic migraine (International Classification of Headache Disorders [ICHD] 1.2.4), sporadic hemiplegic migraine (ICHD 1.2.5) or basilar-type migraine (ICHD 1.2.6).
- •Average of 4 migraine-days/month during the 3 months prior to screening.
- •4 migraine-days during prospective baseline period.
- •At least one of the subject's migraines during the previous 3 months must have been accompanied by their characteristic basilar-type or hemiplegic neurologic symptoms of moderate to severe degree.
- •6-18 years of age.
- •Weigh more than 25 kg.
- •If female, subjects must:
- •be premenarchal or otherwise incapable of pregnancy, or
- •have practiced one of the following methods of contraception for at least one month prior to study entry: hormonal contraceptives, spermicide and barrier, intrauterine device, spousal/partner sterility, or
- •be practicing abstinence and agree to continue abstinence or to use an acceptable method of contraception (as listed above) should sexual activity commence.
- •If (b) or (c), the subject must have a negative urine pregnancy test within one week of study entry.
- •Able to take oral medication in tablet form
- •Willing and able to:
- •read and comprehend written instructions,
- •complete the assessment forms,
- •return for regular visits, and d) adhere to medication regimens.
排除标准
- •Previously failed topiramate therapy for migraine prophylaxis or those who discontinued topiramate due to adverse events.
- •Have taken topiramate within 14 days prior to the start of the prospective baseline period.
- •Have 15 or more headache-days during the prospective baseline period.
- •Have cluster headaches or chronic migraine.
- •Have migraine aura without headache exclusively.
- •Currently have a more painful condition than their migraine pain.
- •Have taken any medications for migraine prophylaxis, within 2 weeks of the start of the prospective baseline period.
- •Progressive neurological disorders or a structural disorder of the brain
- •Overuse analgesic or migraine-specific agents for abortive treatment of migraine:
- •>10 treatment days/month of ergot-containing medication, triptans, or opioids;
- •>15 treatment days/month with simple analgesics (including NSAIDs)
- •Require any injections of corticosteroids or local anesthetics within 60 days of visit 1 or botulinum toxin within 120 days prior to Visit
- •Have previously failed more than 2 adequate trials of an established prophylactic anti-migraine regimen.
- •Subjects starting non-pharmacologic prophylactic approaches within 1 month prior to Visit
- •Non-pharmacologic prophylactic approaches started at least 1 month prior to Visit 1 should be continued throughout the study.
- •Have taken carbonic anhydrase inhibitors or triamterene within 1 month prior to Visit
- •History of nephrolithiasis.
- •Require continuing treatment with anticonvulsant therapy for a non-migraine condition.
- •Significant major psychiatric disorder (e.g., major depression) or subjects receiving anti-psychotic medication.
- •History of attempted suicide or suicidal tendencies.
- •History of substance abuse.
- •Pregnant or lactating females.
- •Clinically unstable neurological, cardiovascular, gastrointestinal, musculoskeletal, pulmonary or other disease.
- •Active liver disease.
- •AST and/or ALT levels greater than 2 times the upper limit of normal range.
- •Received an investigational drug or used an investigational device within 30 days of study entry.
结局指标
主要结局
The primary efficacy outcome will be the reduction in average monthly migraine-days over the entire double-blind phase relative to the prospective baseline period
次要结局
- Reduction in frequency, severity and duration of basilar or hemiplegic aura symptoms
- Reduction in migraine pain severity and duration
- Reduction in migraine episode and headache episode frequency
- Reduction in total headache days
- Proportion of responders (i.e., the proportion of subjects who experience a ≥ 50% reduction in migraine-days and migraine episodes)
- Cumulative reduction in frequency of migraine days and migraine episodes
- Reduction in the use of acute/abortive medications
- Reduction in migraine-associated symptoms
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
A Study on Safety and Efficacy of Two Doses of Topiramate as Monotherapy in the Treatment of Newly Diagnosed or Recurrent EpilepsyEpilepsySeizuresEpilepsies, PartialEpilepsy, GeneralizedEpilepsy, Tonic-ClonicNCT00231556Johnson & Johnson Pharmaceutical Research & Development, L.L.C.750
已完成
3 期
A Study of the Effectiveness and Safety of Topiramate for the Prevention of Migraine Attacks in ChildrenVascular HeadachesMigraineNCT00210535Johnson & Johnson Pharmaceutical Research & Development, L.L.C.110
已完成
3 期
A Study of the Efficacy and Safety of Topiramate as an add-on Therapy in the Treatment of Epilepsy Patients With Lennox-Gastaut SyndromeSeizuresEpilepsyNCT00236756Johnson & Johnson Pharmaceutical Research & Development, L.L.C.100
已完成
3 期
A Study of the Efficacy and Safety of Two Doses of Topiramate Compared to Placebo and Propranolol in the Prevention of MigraineCommon MigraineClassic MigraineHeadacheMigraineNCT00236561Johnson & Johnson Pharmaceutical Research & Development, L.L.C.786
已完成
2 期
A Study on Efficacy and Safety of Topiramate in the Treatment of Patients With ObesityObesityNCT00236613Johnson & Johnson Pharmaceutical Research & Development, L.L.C.385